Enhancement of Nucleoside Production in Based on Biosynthetic Pathway Analysis.

Journal: BioMed research international
PMID: 29333435

Abstract

To enhance nucleoside production in , the biosynthetic pathways of purine and pyrimidine nucleosides were constructed and verified. The differential expression analysis showed that , and genes involved in purine nucleotide biosynthesis were significantly upregulated 16.56-fold, 8-fold, and 5.43-fold, respectively. Moreover, , , and genes participating in pyrimidine nucleoside biosynthesis were upregulated 4.53-fold, 10.63-fold, 4.26-fold, and 5.98-fold, respectively. To enhance the nucleoside production, precursors for synthesis of nucleosides were added based on the analysis of biosynthetic pathways. Uridine and cytidine contents, respectively, reached 5.04 mg/g and 3.54 mg/g when adding 2 mg/mL of ribose, resulting in an increase of 28.6% and 296% compared with the control, respectively. Meanwhile, uridine and cytidine contents, respectively, reached 10.83 mg/g 2.12 mg/g when adding 0.3 mg/mL of uracil, leading to an increase of 176.3% and 137.1%, respectively. This report indicated that fermentation regulation was an effective way to enhance the nucleoside production in based on biosynthetic pathway analysis.

Authors

  • Zhi-Qiang Liu
    Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China.
  • Bo Zhang
    Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR China.
  • Shan Lin
    Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China.
  • Peter James Baker
    Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China.
  • Mao-Sheng Chen
    Department of Nephrology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China.
  • Ya-Ping Xue
    Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China.
  • Hui Wu
    China Medical University College of Health Management, Shenyang 110122, Liaoning Province, China.
  • Feng Xu
    Orthopedics Department of the First Affiliated Hospital of Tsinghua University, Beijing, China.
  • Shui-Jin Yuan
    East China Pharmaceutical Group Limited Co., Ltd, Hangzhou 311000, China.
  • Yi Teng
    East China Pharmaceutical Group Limited Co., Ltd, Hangzhou 311000, China.
  • Ling-Fang Wu
    East China Pharmaceutical Group Limited Co., Ltd, Hangzhou 311000, China.
  • Yu-Guo Zheng
    Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China.

Keywords

External Resources

Popular Topics
Recent Journals